Advances in Economics, Management and Political Sciences

- The Open Access Proceedings Series for Conferences


Proceedings of the 3rd International Conference on Business and Policy Studies

Series Vol. 74 , 17 April 2024


Open Access | Article

Financial Statistics Analysis of Microsoft, Apple, Pfizer and Merck

Moyao Chen * 1
1 NYU Tandon, 6 Metrotech Center, Brooklyn, NY 11201, United States United States

* Author to whom correspondence should be addressed.

Advances in Economics, Management and Political Sciences, Vol. 74, 8-13
Published 17 April 2024. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Moyao Chen. Financial Statistics Analysis of Microsoft, Apple, Pfizer and Merck. AEMPS (2024) Vol. 74: 8-13. DOI: 10.54254/2754-1169/74/20241347.

Abstract

The COVID-19 pandemic has had far-reaching effects on global industries. The pandemic's impact on financial performance varied widely across sectors. This report aims to provide a preliminary understanding of the impact of the pandemic on companies in different industries and with different business models. This report selects four other companies, Microsoft, Apple, Pfizer, and Merck, from two different sectors, pharmaceuticals and technology. By comparing companies from these diverse industries, the report gains insights into the different business models reflected in their financial data. The financial statistics examined include annual stock returns, EBIT margin, and EPS. This analysis of technology and pharmaceutical companies' financial data highlights differences in performance and trends. The findings emphasize the significance of operating margin and EPS as key indicators of financial performance across industries. The differing financial performances of these four companies before and after the pandemic are primarily influenced by the characteristics of their respective industries, the nature of their business operations, and their financial strategies.

Keywords

Financial Analysis, EBIT Margin, Pharmaceuticals

References

1. Kimball, S. (2022). The Covid pandemic drives Pfizer’s 2022 revenue to a record $100 billion. Retrieved from https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html.

2. Vernimmen, P., Quiry, P., & Le Fur, Y. (2022). Corporate finance: theory and practice. John Wiley & Sons.

3. Shen, H., Fu, M., Pan, H., Yu, Z., & Chen, Y. (2020). The impact of the COVID-19 pandemic on firm performance. Emerging Markets Finance and Trade, 56(10), 2213-2230.

4. Sausan, F. R., Korawijayanti, L., & Ciptaningtias, A. F. (2020). The effect of return on asset (ROA), debt to equity ratio (DER), earning per share (EPS), total asset turnover (TATO) and exchange rate on stock return of property and real estate companies at Indonesia stock exchange period 2012-2017. Ilomata International Journal of Tax and Accounting, 1(2), 103-114.

5. Duan, H., Wang, S., & Yang, C. (2020). Coronavirus: limit short-term economic damage. Nature, 578(7796), 515-516.

6. Altig, D., Baker, S., Barrero, J. M., Bloom, N., Bunn, P., Chen, S., ... & Thwaites, G. (2020). Economic uncertainty before and during the COVID-19 pandemic. Journal of Public Economics, 191, 104274.

7. Wiederrecht, G. & Darwish, S. & Callaway, A. (2022). Big tech vs big pharma: the tug of war has begun. Retrieved from https://www.rbccm.com/en/gib/healthcare/episode/big_tech_vs_big_pharma.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 3rd International Conference on Business and Policy Studies
ISBN (Print)
978-1-83558-371-5
ISBN (Online)
978-1-83558-372-2
Published Date
17 April 2024
Series
Advances in Economics, Management and Political Sciences
ISSN (Print)
2754-1169
ISSN (Online)
2754-1177
DOI
10.54254/2754-1169/74/20241347
Copyright
17 April 2024
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated